Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452527 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Iconic Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03452527 is a Phase 2 study that was terminated before completion, run by Iconic Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT03452527, a Phase 2 study, was terminated before completion, sponsored by Iconic Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
Interventions
- BIOLOGICAL ICON-1
- BIOLOGICAL aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452527
The ClinicalTrials.gov registry entry for NCT03452527 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iconic Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ICON-1 is the first listed.
NCT03452527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03452527 about?
NCT03452527 is a clinical study titled "Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)". The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
What is the current status of trial NCT03452527?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-03-26. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT03452527?
The interventions under investigation include: ICON-1 (BIOLOGICAL), aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT03452527?
This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.